<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">Brain metastasis</z:e> is infrequent in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, and the prognosis is poor </plain></SENT>
<SENT sid="1" pm="."><plain>In this retrospective study survival and prognostic factors were determined in patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHOD: Between 1997 and 2006, 39 patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastasis</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> who survived more than 1 month were identified </plain></SENT>
<SENT sid="3" pm="."><plain>Data were collected with regard to patient characteristics, location and stage of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e>, extent and location of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e>, and treatment modalities used </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Most (79.5%) patients had <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> before <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastasis</z:e>, and the brain was the site of solitary <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> in only one patient </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequent symptom was <z:mp ids='MP_0000746'>weakness</z:mp> [18 (43.6%) patients] </plain></SENT>
<SENT sid="6" pm="."><plain>Overall median survival was 5.0 months and the 1- and 2-year survival rates were 21.8 and 9.1%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate analysis revealed uncontrolled extracranial <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (P = 0.019), multiple <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">brain lesions</z:e> (P = 0.026), bilateral <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> (P = 0.032) and serum carcinoembryonic antigen levels greater than 5 ng/ml (P = 0.008) to be poor prognostic factors </plain></SENT>
<SENT sid="8" pm="."><plain>The median survival after the diagnosis of <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastasis</z:e> was significantly longer in patients who underwent surgical resection (15.2 Â± 8.0 months) than in those treated by other modalities (P = 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment modality was the only independent prognostic factor for overall survival in patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> from <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> (P = 0.015) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Aggressive surgical resection in selected patients with <z:e sem="disease" ids="C0220650" disease_type="Neoplastic Process" abbrv="">brain metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> may prolong survival, even in the presence of extracranial metastatic lesions </plain></SENT>
</text></document>